@xconomy.com 2 days ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com 23 days ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com 1 month ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com 1 month ago
Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 1 month ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 1 month ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 1 month ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com 1 month ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 2 months ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com 2 months ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 2 months ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 2 months ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com 2 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 3 months ago
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
@xconomy.com 3 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 months ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com 4 months ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 4 months ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 5 months ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com 5 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 5 months ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com 5 months ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com 5 months ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 5 months ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 5 months ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com 5 months ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 6 months ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com 7 months ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com 7 months ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com 8 months ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com 8 months ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com 8 months ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 8 months ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com 8 months ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com 8 months ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com 8 months ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 8 months ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com 9 months ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 9 months ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com 9 months ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com 9 months ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com 9 months ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 9 months ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com 9 months ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com 9 months ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com 10 months ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 10 months ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com 10 months ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More